Bioscience Managers' first fund achieves 24.7% IRR
Bioscience Managers revealed that its Australian Bioscience Fund I healthcare fund has returned capital to investors at an annual internal rate of return of 24.7%.
Since its inception in July 2008, the fund called $35 million and ended with $56 million returned, a closing unit price of $1.76 per dollar invested, the fund manager said.
Australian Bioscience I was the first fund run by Bioscience Managers since it was established from the former IB Managers.
It focused on investments in mid-stage healthcare and life science investments, including Alchemia (ASX:ACL), Bionomics (ASX:BNO), Acrux (ASX:ACR) and HeartWare International (ASX:HIN).
The fund’s minimum commitment was $4 million, and investors included Telstra Super, Asia Union Investments, Meat Industry Employees Superannuation Fund and the ANU.
Bioscience Managers Managing Director Jeremy Curnock Cook said the fund has outperformed the S&P/ASX200 Accumulation Index by 68%, “despite the volatility in the past six years and investing in what is regarded as a high-risk sector”.
The company’s second fund, Asia Pacific Healthcare Fund II, will have its final close in September. The fund seeks to raise up to $100 million and has invested in companies including Nexvet Biopharma, Avita Medical (ASX:AVH), AmpliPhi Biosciences and Rex Bionics
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
